Investment Landscape: Calcium Signaling covers the current R&D investment, clinical trial pipeline, and therapeutic approaches targeting calcium signaling dysregulation in neurodegenerative diseases. Calcium homeostasis is critical for neuronal function, and its disruption is implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[1].
Last updated: 2026-03-15
Calcium signaling represents a fundamental pathway in neuronal health and disease. Dysregulation of calcium homeostasis contributes to:
The therapeutic landscape targeting calcium signaling includes multiple approaches: calcium channel blockers, calcium homeostasis modulators, calcium-sensing receptor agonists, and mitochondrial calcium uptake inhibitors[2].
Current clinical trials targeting calcium signaling mechanisms remain limited compared to other therapeutic approaches. The focus has been primarily on repurposing existing cardiovascular calcium channel blockers for neurodegenerative indications, with mixed results in clinical trials.
| Status | Count |
|---|---|
| Recruiting | 5-10 |
| Active, Not Recruiting | 3-5 |
| Completed | 15-20 |
| Terminated/Withdrawn | 10-15 |
| Phase | Approximate Trials |
|---|---|
| Phase 1 | 5-8 |
| Phase 2 | 10-15 |
| Phase 3 | 3-5 |
Calcium channel blockers (CCBs) represent the most advanced approach to targeting calcium dysregulation in neurodegeneration:
Key Companies: Novartis, Pfizer, Biogen, Axsome Therapeutics
Clinical Status: Several Phase 2/3 trials completed for AD and PD; mixed results
Novel approaches to restore calcium homeostasis:
Key Companies: NeuroKey, Catapult Therapeutics, Svizera
Clinical Status: Mostly preclinical to Phase 1
Targeting extrasynaptic calcium signaling:
Key Companies: Amgen, Shionogi
Clinical Status: Early preclinical
Calcium dysregulation is an early event in AD pathogenesis, contributing to amyloid-beta and tau pathology:
Calcium dysregulation contributes to dopaminergic neuron vulnerability:
Calcium dysregulation in motor neurons:
Annual NIH funding for calcium signaling in neurodegeneration:
Funding Focus: Basic biology, translational research, clinical trials
| Company | Approach | Development Stage | Market Position |
|---|---|---|---|
| Novartis | L-type CCB | Phase 2/3 | Established |
| Biogen | Calcium modulation | Phase 1 | Emerging |
| Axsome Therapeutics | Novel mechanisms | Phase 2 | Disruptor |
| NeuroKey | SERCA activators | Preclinical | Early stage |
Calcium dysregulation in the pathogenesis of Alzheimer's disease: recent advances. Nature Reviews Neurology. 2022. ↩︎
Calcium signaling in Parkinson's disease: new insights and therapeutic opportunities. Movement Disorders. 2023. ↩︎